Shu Jin

741 total citations · 1 hit paper
16 papers, 346 citations indexed

About

Shu Jin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Shu Jin has authored 16 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Shu Jin's work include Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). Shu Jin is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). Shu Jin collaborates with scholars based in United States, China and Taiwan. Shu Jin's co-authors include Jianchang Lin, Danny Nguyen, Minal Mehta, Huamao Mark Lin, Veronica Bunn, Pasi A. Jänne, Suresh S. Ramalingam, James Chih‐Hsin Yang, Tarek Mekhail and Gregory J. Riely and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Thoracic Oncology.

In The Last Decade

Shu Jin

16 papers receiving 337 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

2021 196 citations Caicun Zhou, Suresh S. Ramalingam et al. JAMA Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shu Jin United States	8	310	256	100	81	20	16	346
Minal Mehta United States	9	310 1.0×	290 1.1×	93 0.9×	85 1.0×	19 0.9×	19	383
M.R. García Campelo Spain	9	301 1.0×	284 1.1×	119 1.2×	90 1.1×	32 1.6×	35	387
You Lu China	9	298 1.0×	251 1.0×	59 0.6×	46 0.6×	19 0.9×	22	338
Luckson Mathieu United States	8	254 0.8×	290 1.1×	157 1.6×	75 0.9×	61 3.0×	12	526
Luis Paz-Ares Rodríguez Spain	7	162 0.5×	183 0.7×	84 0.8×	43 0.5×	21 1.1×	15	310
Claudio Sini Italy	15	227 0.7×	235 0.9×	163 1.6×	128 1.6×	25 1.3×	28	440
Kosei Tajima Japan	8	611 2.0×	529 2.1×	150 1.5×	98 1.2×	24 1.2×	15	706
Kim-Son H. Nguyen United States	4	295 1.0×	265 1.0×	203 2.0×	108 1.3×	19 0.9×	7	432
L. Paz-Ares Spain	9	215 0.7×	291 1.1×	97 1.0×	40 0.5×	38 1.9×	51	374
M.C. Garassino Italy	5	327 1.1×	267 1.0×	71 0.7×	90 1.1×	8 0.4×	13	367

Countries citing papers authored by Shu Jin

Since Specialization

Citations

This map shows the geographic impact of Shu Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Jin more than expected).

Fields of papers citing papers by Shu Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Jin. The network helps show where Shu Jin may publish in the future.

Co-authorship network of co-authors of Shu Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Shu Jin. A scholar is included among the top collaborators of Shu Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Jin. Shu Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison. Lung Cancer. 179. 107186–107186. 4 indexed citations

Christopoulos, Petros, Jin‐Liern Hong, Huamao Mark Lin, et al.. (2023). Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer. 179. 107191–107191. 3 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations. JTO Clinical and Research Reports. 4(10). 100558–100558. 25 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2023). Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non–Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison. Clinical Lung Cancer. 25(3). e145–e152.e3. 3 indexed citations

Jänne, Pasi A., Suresh S. Ramalingam, James Chih‐Hsin Yang, et al.. (2022). Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.. Journal of Clinical Oncology. 40(16_suppl). 9099–9099. 6 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2022). Matching-adjusted indirect comparison (MAIC) of mobocertinib versus amivantamab in patients with non–small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins).. Journal of Clinical Oncology. 40(16_suppl). 9115–9115. 3 indexed citations

Zhou, C., Suresh S. Ramalingam, Jian Fang, et al.. (2021). OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations. Journal of Thoracic Oncology. 16(3). S108–S108. 21 indexed citations

Ou, Sai‐Hong Ignatius, Huamao Mark Lin, Jin‐Liern Hong, et al.. (2021). Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.. Journal of Clinical Oncology. 39(15_suppl). 9098–9098. 20 indexed citations

Jänne, Pasi A., Suresh S. Ramalingam, James Chih‐Hsin Yang, et al.. (2021). FP09.01 Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy. Journal of Thoracic Oncology. 16(10). S960–S960. 2 indexed citations

10.

Zhou, Caicun, Suresh S. Ramalingam, Tae Min Kim, et al.. (2021). Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer. JAMA Oncology. 7(12). e214761–e214761. 196 indexed citations breakdown →

11.

Zhang, Steven, Shu Jin, Jianchang Lin, et al.. (2021). Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. Clinical Pharmacology in Drug Development. 10(9). 1028–1043. 11 indexed citations

12.

Zhang, Steven, et al.. (2021). Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK‐788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers. Clinical Pharmacology in Drug Development. 10(9). 1044–1053. 13 indexed citations

13.

Ramalingam, Suresh S., Caicun Zhou, Tae Min Kim, et al.. (2021). Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.. Journal of Clinical Oncology. 39(15_suppl). 9014–9014. 18 indexed citations

14.

Spira, Alexander I., Joel W. Neal, Zofia Piotrowska, et al.. (2021). OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy. Journal of Thoracic Oncology. 16(10). S873–S874. 3 indexed citations

15.

Riely, Greg J., Joel W. Neal, D. Ross Camidge, et al.. (2020). 1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins). Annals of Oncology. 31. S815–S816. 15 indexed citations

16.

Riely, Gregory J., Joel W. Neal, D. Ross Camidge, et al.. (2019). P1.01-127 Antitumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 in NSCLC with EGFR Exon 20 Insertions. Journal of Thoracic Oncology. 14(10). S412–S413. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact